Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Artivion, Inc. (AORT) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Artivion, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 784199.
Total stock buying since 2015: $883,118.
Total stock sales since 2015: $62,379,049.
Total stock option exercises since 2015: $17,330,448.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2026 | 0 | $0 | 133,043 | $4,977,137 | 0 | $0 |
| 2025 | 2,100 | $53,106 | 610,510 | $22,311,263 | 319,378 | $7,058,077 |
| 2024 | 0 | $0 | 234,400 | $4,971,272 | 85,217 | $1,454,293 |
| 2023 | 0 | $0 | 204,772 | $2,858,155 | 146,226 | $1,584,598 |
| 2022 | 0 | $0 | 58,702 | $1,088,574 | 42,553 | $468,083 |
| 2021 | 15,600 | $270,797 | 160,366 | $4,530,470 | 119,275 | $1,451,697 |
| 2020 | 20,000 | $332,730 | 56,285 | $1,335,284 | 48,651 | $482,194 |
| 2019 | 5,000 | $117,355 | 128,222 | $3,889,005 | 54,986 | $420,534 |
| 2018 | 0 | $0 | 339,333 | $10,498,114 | 256,143 | $2,381,974 |
| 2017 | 0 | $0 | 237,993 | $4,890,608 | 118,667 | $655,474 |
| 2016 | 10,000 | $109,130 | 43,000 | $474,600 | 85,033 | $526,144 |
| 2015 | 0 | $0 | 51,698 | $554,567 | 95,550 | $847,380 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2026-03 | 0 | $0 | 71,841 | $2,722,643 | 0 | $0 |
| 2026-02 | 0 | $0 | 61,202 | $2,254,494 | 0 | $0 |
| 2025-12 | 0 | $0 | 78,729 | $3,574,430 | 61,842 | $1,831,760 |
| 2025-11 | 0 | $0 | 176,427 | $7,998,449 | 82,950 | $1,565,885 |
| 2025-08 | 0 | $0 | 82,850 | $3,557,930 | 63,969 | $1,276,637 |
| 2025-06 | 0 | $0 | 41,132 | $1,185,798 | 0 | $0 |
| 2025-05 | 0 | $0 | 31,822 | $922,836 | 0 | $0 |
| 2025-03 | 2,100 | $53,106 | 134,333 | $3,291,008 | 110,617 | $2,383,795 |
| 2025-02 | 0 | $0 | 65,217 | $1,780,812 | 0 | $0 |
| 2024-12 | 0 | $0 | 20,017 | $600,046 | 0 | $0 |
| 2024-10 | 0 | $0 | 12,430 | $325,417 | 12,430 | $267,866 |
| 2024-08 | 0 | $0 | 24,679 | $626,555 | 0 | $0 |
| 2024-05 | 0 | $0 | 2,229 | $52,560 | 0 | $0 |
| 2024-03 | 0 | $0 | 28,773 | $550,305 | 0 | $0 |
| 2024-02 | 0 | $0 | 132,710 | $2,572,273 | 59,225 | $965,367 |
| 2024-01 | 0 | $0 | 13,562 | $244,116 | 13,562 | $221,060 |
| 2023-12 | 0 | $0 | 14,397 | $273,543 | 14,397 | $234,671 |
| 2023-11 | 0 | $0 | 2,101 | $36,431 | 0 | $0 |
| 2023-06 | 0 | $0 | 22,583 | $349,236 | 0 | $0 |
| 2023-03 | 0 | $0 | 18,497 | $248,076 | 0 | $0 |
| 2023-02 | 0 | $0 | 147,194 | $1,950,869 | 131,829 | $1,349,927 |
| 2022-12 | 0 | $0 | 3,226 | $43,783 | 0 | $0 |
| 2022-08 | 0 | $0 | 12,923 | $288,977 | 0 | $0 |
| 2022-02 | 0 | $0 | 42,553 | $755,814 | 42,553 | $468,083 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-03-04 | Holloway Jean F (SVP, General Counsel) | Sale | 8,962 | 38.00 | 340,556 |
| 2026-03-03 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 2,149 | 37.78 | 81,180 |
| 2026-03-03 | Davis John E (Chief Commercial Officer) | Sale | 4,573 | 37.78 | 172,749 |
| 2026-03-03 | Holloway Jean F (SVP, General Counsel) | Sale | 3,843 | 37.78 | 145,173 |
| 2026-03-03 | Berry Lance A (EVP, COO, CFO & Treasurer) | Sale | 6,316 | 37.78 | 238,593 |
| 2026-03-03 | Mackin James P (President & CEO) | Sale | 17,887 | 37.78 | 675,699 |
| 2026-03-03 | Horton Amy (VP, Chief Accounting Officer) | Sale | 901 | 37.78 | 34,036 |
| 2026-03-02 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 1,513 | 38.02 | 57,531 |
| 2026-03-02 | Davis John E (Chief Commercial Officer) | Sale | 2,784 | 38.02 | 105,861 |
| 2026-03-02 | Holloway Jean F (SVP, General Counsel) | Sale | 2,183 | 38.02 | 83,008 |
| 2026-03-02 | Berry Lance A (EVP, COO, CFO & Treasurer) | Sale | 5,178 | 38.02 | 196,893 |
| 2026-03-02 | Mackin James P (President & CEO) | Sale | 14,911 | 38.02 | 566,990 |
| 2026-03-02 | Horton Amy (VP, Chief Accounting Officer) | Sale | 641 | 38.02 | 24,374 |
| 2026-02-24 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 1,259 | 35.69 | 44,937 |
| 2026-02-24 | Davis John E (Chief Commercial Officer) | Sale | 2,075 | 35.69 | 74,062 |
| 2026-02-24 | Holloway Jean F (SVP, General Counsel) | Sale | 1,668 | 35.69 | 59,535 |
| 2026-02-24 | Berry Lance A (EVP, COO, CFO & Treasurer) | Sale | 4,485 | 35.69 | 160,083 |
| 2026-02-24 | Mackin James P (President & CEO) | Sale | 13,936 | 35.69 | 497,417 |
| 2026-02-24 | Horton Amy (VP, Chief Accounting Officer) | Sale | 830 | 35.69 | 29,625 |
| 2026-02-23 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 2,423 | 37.59 | 91,075 |
| 2026-02-23 | Davis John E (Chief Commercial Officer) | Sale | 3,773 | 37.59 | 141,819 |
| 2026-02-23 | Holloway Jean F (SVP, General Counsel) | Sale | 3,079 | 37.59 | 115,733 |
| 2026-02-23 | Berry Lance A (EVP, COO, CFO & Treasurer) | Sale | 4,981 | 37.59 | 187,225 |
| 2026-02-23 | Mackin James P (President & CEO) | Sale | 20,962 | 37.59 | 787,919 |
| 2026-02-23 | Horton Amy (VP, Chief Accounting Officer) | Sale | 1,731 | 37.59 | 65,064 |
| 2025-12-15 | Davis John E (Chief Commercial Officer) | Sale | 5,000 | 45.11 | 225,550 |
| 2025-12-08 | Horton Amy (VP, Chief Accounting Officer) | Sale | 4,572 | 44.42 | 203,083 |
| 2025-12-03 | Holloway Jean F (SVP, General Counsel) | Sale | 7,315 | 45.30 | 331,369 |
| 2025-12-03 | Mackin James P (President & CEO) | Sale | 30,921 | 45.46 | 1,405,699 |
| 2025-12-03 | Mackin James P (President & CEO) | Option Ex | 30,921 | 29.62 | 915,880 |
| 2025-12-02 | Mackin James P (President & CEO) | Sale | 30,921 | 45.56 | 1,408,729 |
| 2025-12-02 | Mackin James P (President & CEO) | Option Ex | 30,921 | 29.62 | 915,880 |
| 2025-11-21 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 47,376 | 45.13 | 2,138,078 |
| 2025-11-21 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Option Ex | 47,376 | 14.73 | 698,085 |
| 2025-11-18 | Hoff Elizabeth A (Director) | Sale | 4,200 | 45.10 | 189,411 |
| 2025-11-17 | Davis John E (Chief Commercial Officer) | Sale | 6,394 | 45.17 | 288,816 |
| 2025-11-17 | Davis John E (Chief Commercial Officer) | Option Ex | 6,394 | 29.62 | 189,390 |
| 2025-11-17 | Holloway Jean F (SVP, General Counsel) | Sale | 6,394 | 45.17 | 288,816 |
| 2025-11-17 | Holloway Jean F (SVP, General Counsel) | Option Ex | 6,394 | 29.62 | 189,390 |
| 2025-11-17 | Horton Amy (VP, Chief Accounting Officer) | Sale | 6,000 | 45.73 | 274,380 |
| 2025-11-14 | Davis John E (Chief Commercial Officer) | Sale | 6,393 | 44.67 | 285,575 |
| 2025-11-14 | Davis John E (Chief Commercial Officer) | Option Ex | 6,393 | 29.62 | 189,360 |
| 2025-11-14 | Holloway Jean F (SVP, General Counsel) | Sale | 6,393 | 45.00 | 287,685 |
| 2025-11-14 | Holloway Jean F (SVP, General Counsel) | Option Ex | 6,393 | 29.62 | 189,360 |
| 2025-11-13 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 4,993 | 45.86 | 228,968 |
| 2025-11-13 | Davis John E (Chief Commercial Officer) | Sale | 6,563 | 45.86 | 300,966 |
| 2025-11-13 | Holloway Jean F (SVP, General Counsel) | Sale | 5,761 | 45.86 | 264,187 |
| 2025-11-13 | Mackin James P (President & CEO) | Sale | 34,210 | 45.86 | 1,568,802 |
| 2025-11-13 | Horton Amy (VP, Chief Accounting Officer) | Sale | 3,482 | 45.86 | 159,677 |
| 2025-11-11 | Holloway Jean F (SVP, General Counsel) | Sale | 10,000 | 46.18 | 461,800 |
| 2025-11-11 | Holloway Jean F (SVP, General Counsel) | Option Ex | 10,000 | 11.03 | 110,300 |
| 2025-11-10 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 2,566 | 44.62 | 114,492 |
| 2025-11-10 | Davis John E (Chief Commercial Officer) | Sale | 3,373 | 44.62 | 150,499 |
| 2025-11-10 | Holloway Jean F (SVP, General Counsel) | Sale | 2,960 | 44.62 | 132,072 |
| 2025-11-10 | Mackin James P (President & CEO) | Sale | 17,580 | 44.62 | 784,402 |
| 2025-11-10 | Horton Amy (VP, Chief Accounting Officer) | Sale | 1,789 | 44.62 | 79,823 |
| 2025-08-27 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 18,200 | 44.02 | 801,218 |
| 2025-08-27 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Option Ex | 18,200 | 11.03 | 200,746 |
| 2025-08-25 | Holloway Jean F (SVP, General Counsel) | Sale | 10,000 | 44.37 | 443,700 |
| 2025-08-25 | Holloway Jean F (SVP, General Counsel) | Option Ex | 10,000 | 11.03 | 110,300 |
| 2025-08-15 | Mackin James P (President & CEO) | Sale | 12,500 | 42.32 | 528,987 |
| 2025-08-12 | Davis John E (Chief Commercial Officer) | Sale | 10,802 | 43.67 | 471,755 |
| 2025-08-12 | Davis John E (Chief Commercial Officer) | Option Ex | 10,802 | 26.24 | 283,444 |
| 2025-08-12 | Holloway Jean F (SVP, General Counsel) | Sale | 23,356 | 43.02 | 1,004,658 |
| 2025-08-12 | Holloway Jean F (SVP, General Counsel) | Option Ex | 16,975 | 26.24 | 445,424 |
| 2025-08-08 | Horton Amy (VP, Chief Accounting Officer) | Sale | 7,992 | 38.49 | 307,612 |
| 2025-08-08 | Horton Amy (VP, Chief Accounting Officer) | Option Ex | 7,992 | 29.62 | 236,723 |
| 2025-06-17 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 15,000 | 29.50 | 442,500 |
| 2025-06-13 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 26,132 | 28.44 | 743,298 |
| 2025-05-27 | Holloway Jean F (SVP, General Counsel) | Sale | 8,748 | 29.00 | 253,692 |
| 2025-05-23 | Semedo Anthony B. (Director) | Sale | 2,600 | 28.47 | 74,027 |
| 2025-05-21 | Holloway Jean F (SVP, General Counsel) | Sale | 9,926 | 29.00 | 287,854 |
| 2025-05-09 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 10,548 | 29.13 | 307,263 |
| 2025-03-11 | Davis John E (Chief Commercial Officer) | Sale | 15,100 | 23.61 | 356,556 |
| 2025-03-11 | Davis John E (Chief Commercial Officer) | Option Ex | 15,910 | 21.55 | 342,860 |
| 2025-03-11 | Holloway Jean F (SVP, General Counsel) | Sale | 18,020 | 23.61 | 425,506 |
| 2025-03-11 | Holloway Jean F (SVP, General Counsel) | Option Ex | 19,092 | 21.55 | 411,432 |
| 2025-03-06 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 1,603 | 24.80 | 39,760 |
| 2025-03-06 | Davis John E (Chief Commercial Officer) | Sale | 2,618 | 24.80 | 64,939 |
| 2025-03-06 | Holloway Jean F (SVP, General Counsel) | Sale | 2,124 | 24.80 | 52,685 |
| 2025-03-06 | Berry Lance A (Executive VP, CFO) | Sale | 4,909 | 24.80 | 121,762 |
| 2025-03-06 | Mackin James P (President & CEO) | Sale | 88,439 | 24.78 | 2,191,872 |
| 2025-03-06 | Mackin James P (President & CEO) | Option Ex | 75,615 | 21.55 | 1,629,503 |
| 2025-03-06 | Horton Amy (VP, Chief Accounting Officer) | Sale | 1,048 | 24.80 | 25,994 |
| 2025-03-05 | Semedo Anthony B. (Director) | Buy | 2,100 | 25.29 | 53,106 |
| 2025-03-05 | Holloway Jean F (SVP, General Counsel) | Sale | 472 | 25.29 | 11,934 |
| 2025-02-24 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 4,687 | 27.31 | 127,983 |
| 2025-02-24 | Davis John E (Chief Commercial Officer) | Sale | 6,457 | 27.31 | 176,314 |
| 2025-02-24 | Holloway Jean F (SVP, General Counsel) | Sale | 5,335 | 27.31 | 145,677 |
| 2025-02-24 | Berry Lance A (Executive VP, CFO) | Sale | 3,259 | 27.31 | 88,990 |
| 2025-02-24 | Mackin James P (President & CEO) | Sale | 42,156 | 27.31 | 1,151,111 |
| 2025-02-24 | Horton Amy (VP, Chief Accounting Officer) | Sale | 3,323 | 27.31 | 90,737 |
| 2024-12-11 | Holloway Jean F (SVP, General Counsel) | Sale | 8,070 | 30.12 | 243,108 |
| 2024-12-06 | Horton Amy (VP, Chief Accounting Officer) | Sale | 4,329 | 29.66 | 128,398 |
| 2024-12-04 | Green Andrew M (VP Regulatory) | Sale | 7,618 | 30.00 | 228,540 |
| 2024-10-01 | Horton Amy (VP, Chief Accounting Officer) | Sale | 12,430 | 26.18 | 325,417 |
| 2024-10-01 | Horton Amy (VP, Chief Accounting Officer) | Option Ex | 12,430 | 21.55 | 267,866 |
| 2024-08-26 | Holloway Jean F (SVP, General Counsel) | Sale | 3,167 | 26.55 | 84,096 |
| 2024-08-16 | Getz Matthew A (VP, Human Resources) | Sale | 9,420 | 25.31 | 238,439 |
| 2024-08-15 | Holloway Jean F (SVP, General Counsel) | Sale | 2,383 | 25.76 | 61,393 |
| 2024-08-13 | Semedo Anthony B. (Director) | Sale | 9,709 | 24.99 | 242,627 |
| 2024-05-10 | Holloway Jean F (SVP, General Counsel) | Sale | 1,250 | 23.42 | 29,275 |
| 2024-05-09 | Holloway Jean F (SVP, General Counsel) | Sale | 979 | 23.79 | 23,285 |
| 2024-03-20 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 2,183 | 20.39 | 44,511 |
| 2024-03-15 | Green Andrew M (VP Regulatory) | Sale | 1,462 | 20.00 | 29,240 |
| 2024-03-12 | Getz Matthew A (VP, Human Resources) | Sale | 5,000 | 19.94 | 99,720 |
| 2024-03-05 | Maney Rochelle L. (VP, Quality) | Sale | 1,157 | 18.72 | 21,661 |
| 2024-03-05 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 1,506 | 18.72 | 28,195 |
| 2024-03-05 | Getz Matthew A (VP, Human Resources) | Sale | 1,157 | 18.72 | 21,661 |
| 2024-03-05 | Mackin James P (President & CEO) | Sale | 13,996 | 18.72 | 262,033 |
| 2024-03-05 | Horton Amy (VP, Chief Accounting Officer) | Sale | 1,152 | 18.72 | 21,567 |
| 2024-03-05 | Green Andrew M (VP Regulatory) | Sale | 1,160 | 18.72 | 21,717 |
| 2024-02-27 | Tyrs Florian (VP, Global Operations) | Sale | 339 | 19.83 | 6,723 |
| 2024-02-27 | Maney Rochelle L. (VP, Quality) | Sale | 370 | 19.84 | 7,338 |
| 2024-02-27 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 465 | 19.83 | 9,222 |
| 2024-02-27 | Getz Matthew A (VP, Human Resources) | Sale | 325 | 19.83 | 6,446 |
| 2024-02-27 | Davis John E (Chief Commercial Officer) | Sale | 584 | 19.83 | 11,583 |
| 2024-02-27 | Holloway Jean F (SVP, General Counsel) | Sale | 1,455 | 19.83 | 28,857 |
| 2024-02-27 | Mackin James P (President & CEO) | Sale | 4,837 | 19.84 | 95,941 |
| 2024-02-27 | Horton Amy (VP, Chief Accounting Officer) | Sale | 325 | 19.83 | 6,446 |
| 2024-02-27 | Green Andrew M (VP Regulatory) | Sale | 421 | 19.83 | 8,350 |
| 2024-02-26 | Tyrs Florian (VP, Global Operations) | Sale | 893 | 20.27 | 18,102 |
| 2024-02-26 | Maney Rochelle L. (VP, Quality) | Sale | 2,315 | 20.27 | 46,927 |
| 2024-02-26 | Getz Matthew A (VP, Human Resources) | Sale | 2,313 | 20.27 | 46,886 |
| 2024-02-26 | Holloway Jean F (SVP, General Counsel) | Sale | 2,880 | 20.27 | 58,380 |
| 2024-02-26 | Mackin James P (President & CEO) | Sale | 31,312 | 20.27 | 634,725 |
| 2024-02-26 | Green Andrew M (VP Regulatory) | Sale | 2,403 | 20.27 | 48,711 |
| 2024-02-20 | Tyrs Florian (VP, Global Operations) | Sale | 249 | 18.86 | 4,697 |
| 2024-02-20 | Maney Rochelle L. (VP, Quality) | Sale | 407 | 18.86 | 7,678 |
| 2024-02-20 | Davis John E (Chief Commercial Officer) | Sale | 2,556 | 18.86 | 48,218 |
| 2024-02-20 | Holloway Jean F (SVP, General Counsel) | Sale | 3,527 | 18.86 | 66,536 |
| 2024-02-20 | Mackin James P (President & CEO) | Sale | 72,069 | 18.86 | 1,359,293 |
| 2024-02-20 | Mackin James P (President & CEO) | Option Ex | 59,225 | 16.30 | 965,367 |
| 2024-02-20 | Horton Amy (VP, Chief Accounting Officer) | Sale | 1,695 | 18.86 | 31,976 |
| 2024-01-02 | Davis John E (Senior VP, Global Sales) | Sale | 13,562 | 18.00 | 244,116 |
| 2024-01-02 | Davis John E (Senior VP, Global Sales) | Option Ex | 13,562 | 16.30 | 221,060 |
| 2023-12-15 | Horton Amy (VP, Chief Accounting Officer) | Sale | 14,397 | 19.00 | 273,543 |
| 2023-12-15 | Horton Amy (VP, Chief Accounting Officer) | Option Ex | 14,397 | 16.30 | 234,671 |
| 2023-11-27 | Horton Amy (VP, Chief Accounting Officer) | Sale | 2,101 | 17.34 | 36,431 |
| 2023-06-07 | Getz Matthew A (VP, Human Resources) | Sale | 6,329 | 15.88 | 100,485 |
| 2023-06-06 | Maier Dennis B (SVP, Operations) | Sale | 16,254 | 15.30 | 248,751 |
| 2023-03-02 | Maney Rochelle L. (VP, Quality) | Sale | 821 | 13.41 | 11,011 |
| 2023-03-02 | Stanton Marshall S. (SVP, Clinical & MD Affair) | Sale | 907 | 13.41 | 12,164 |
| 2023-03-02 | Getz Matthew A (VP, Human Resources) | Sale | 702 | 13.41 | 9,415 |
| 2023-03-02 | Maier Dennis B (SVP, Operations) | Sale | 1,121 | 13.41 | 15,034 |
| 2023-03-02 | Davis John E (Senior VP, Global Sales) | Sale | 1,121 | 13.41 | 15,034 |
| 2023-03-02 | Holloway Jean F (SVP, General Counsel) | Sale | 907 | 13.41 | 12,164 |
| 2023-03-02 | Mackin James P (President & CEO) | Sale | 9,990 | 13.41 | 133,985 |
| 2023-03-02 | Horton Amy (VP, Chief Accounting Officer) | Sale | 702 | 13.41 | 9,415 |
| 2023-03-02 | Green Andrew M (VP Regulatory) | Sale | 825 | 13.41 | 11,064 |
Insider trading activities including stock purchases, stock sales, and option exercises of AORT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Artivion, Inc. (symbol AORT, CIK number 784199) see the Securities and Exchange Commission (SEC) website.